Vidcast:  https://www.instagram.com/p/DQ7kB3aF64K/

If rejecting a CoVid vaccine that helps you avoid CoVid infection which could land you on a ventilator or in the morgue wasn’t incentive enough to get the jab, oncologists at the University of Texas MD Anderson Cancer Center and University of Florida report that COVID-19 mRNA vaccines dramatically improve survival for lung cancer and melanoma patients with advanced, metastatic disease. 

Their study, published in the journal Nature, demonstrates that patients receiving a COVID mRNA vaccine within 100 days of initiating immunotherapy lived significantly longer—in some cases, nearly twice as long—as those who were unvaccinated. These survival curves for lung cancer and for melanoma instantly tell this amazing story.

The CoVid mRNA vaccines apparently turbocharge a cancer patient’s immune system in nonspecific way that assists immunotherapy. For lung cancer patients, mean survivals climbed from 20 to 37 months and 3 year survivals jumped from 31% to 56%. For melanoma patients, progression-free survival increased from 4 to 10 months and 3 year progression-free  survival advanced from 24% to 40%. Control groups receiving non-mRNA vaccines including those for influenza and pneumonia failed to enjoy similar benefits.

To confirm this phenomenon, a larger clinical trial is now in the planning stage. If the results are consistent, it could be possible to develop a universal mRNA cancer vaccine..

https://www.sciencedaily.com/releases/2025/10/251027224837.htm

Grippin, A.J., Marconi, C., Copling, S. et al. SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade. Nature (2025). https://doi.org/10.1038/s41586-025-09655-y

#mrna #vaccine #CoVid #cancer #lungca #melanoma